20/20 Biolabs, Inc. 8K

20/20 BioResponse, Inc. used an investor presentation attached to its Form 8-K to describe its OneTest MCED strategy, regulatory and reimbursement pathway under the new 2028 Medicare coverage framework, supporting evidence plans, and contingent growth and M&A projections.

The Form 8-K includes an investor presentation by 20/20 BioResponse, Inc. (NASDAQ: AIDX) dated July 1, 2026, outlining its OneTest multi-cancer early detection (MCED) strategy, the potential impact of the newly enacted Multi-Cancer Early Detection Screening Coverage Act that creates a statutory pathway for Medicare reimbursement of MCED blood tests beginning in 2028, and the company’s planned regulatory and evidence-development approach for FDA authorization and CMS coverage. The presentation contrasts OneTest’s protein biomarker and machine-learning approach with Grail’s ctDNA-based Galleri trial results, describes current real-world data generation through large international cohorts and over 30,000 U.S. firefighters, and presents hypothetical modeled sensitivity/specificity metrics and revenue projections contingent on successful FDA and CMS outcomes. It also outlines a merger and acquisition strategy to “bolt-on” vertically or horizontally integrated health and wellness businesses, and includes forward-looking statements, emphasizing that OneTest is currently an LDT without FDA De Novo or PMA approval and that Medicare reimbursement under the new Act is not assured.

Filing Facts

CIK

1139685

Ticker

-

Form

8K

Source Type

sec

Accession

0001213900-26-074182

Alert Tier

5